Plasma Concentration Studies
SEMAX / SELANK
ACTH (4-10)
ACTH (4-7)-Pro-Gly-Pro
Met-Glu-His-Phe-Pro-Gly-Pro
MEHFPGP
CAS: 80714-61-0
A 7-amino acid synthetic heptapeptide analog of ACTH (4-10) that upregulates BDNF expression and modulates the TrkB signaling pathway, studied for cognitive enhancement and neuroprotection in clinical research. Premium Research Peptide.

99%+ Purity
Purity Tested
Research Use Only
Laboratory Use
Peptide Profile
Peptide Type
Certificate of Analysis
Third Party Tested by Freedom Diagnostics
Compound Information
Technical specifications
What Is Semax?
Synthetic heptapeptide analog of ACTH (4-10) with C-terminal Pro-Gly-Pro extension for enhanced stability
Stability Information
Handle with care to maintain potency
Lyophilized (powder)
-20°C • up to 2 years
Reconstituted
2-8°C • use within 4 weeks
Nasal spray (0.15%)
2-8°C • 30 days after opening
Sources & References
Peer-reviewed research
Brain Research
Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat...
2006 • DOI: 10.1016/j.bra...
PMID: 16996037
Dolotov OV, Karpenko EA, Inozemtseva
- View Source
BMC Genomics
The peptide semax affects the expression of genes related to the immune and vascular systems in rat...
2014 • DOI: 10.1186/1471-...
PMID: 24661656
Medvedeva EV, Dmitrieva VG,
- View Source
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
The efficacy of semax in the treatment of patients at different stages of ischemic stroke
2018
PMID: 29798983
- View Source
Journal of Molecular Neuroscience
Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus,...
2010 • DOI: 10.1007/s120...
PMID: 19662538
Shadrina M, Kolomin T, Agapova T, et...
- View Source
International Journal of Molecular Sciences
Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Molecular Level
2020
PMID: 32575851
- View Source
Alzheimer's Drug Discovery Foundation
Semax - Cognitive Vitality For Researchers
- View Source
PubChem Database
Semax - Compound Summary (CID 9811102)
- View Source




